March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
Genetic Screening of LOXL1 Polymorphisms in Exfoliation Syndrome (XFS) Suspects (XFSS)
Author Affiliations & Notes
  • Cinthi Pillai
    Einhorn Clinical Research Center, New York Eye and Ear Infirmary, New York, New York
  • Waseem A. Aalam
    Ophthalmology Department, Taibah University, Medina, Saudi Arabia
  • Timothy Sullivan
    Einhorn Clinical Research Center, New York Eye and Ear Infirmary, New York, New York
  • Jeffrey M. Liebmann
    Einhorn Clinical Research Center, New York Eye and Ear Infirmary, New York, New York
  • Roshanak Sharafieh
    Molecular Ophthalmic Genetics, University of Connecticut Health Center, Farmington, Connecticut
  • Mansoor Sarfarazi
    Molecular Ophthalmic Genetics, University of Connecticut Health Center, Farmington, Connecticut
  • Robert Ritch
    Einhorn Clinical Research Center, New York Eye and Ear Infirmary, New York, New York
  • Footnotes
    Commercial Relationships  Cinthi Pillai, None; Waseem A. Aalam, None; Timothy Sullivan, None; Jeffrey M. Liebmann, None; Roshanak Sharafieh, None; Mansoor Sarfarazi, None; Robert Ritch, None
  • Footnotes
    Support  Joseph M. Cohen Research Fund of the New York Glaucoma Research Institute, New York, NY.
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 1536. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Cinthi Pillai, Waseem A. Aalam, Timothy Sullivan, Jeffrey M. Liebmann, Roshanak Sharafieh, Mansoor Sarfarazi, Robert Ritch; Genetic Screening of LOXL1 Polymorphisms in Exfoliation Syndrome (XFS) Suspects (XFSS). Invest. Ophthalmol. Vis. Sci. 2012;53(14):1536.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose:
 

To assess the potential value of LOXL1 screening in patients with no clinically visible exfoliation material in either eye but with other findings suggestive of XFS.

 
Methods:
 

We genotyped 17 XFSS for 3 single nucleotide polymorphisms (SNPs; rs3825942, rs1048661 and rs2165241) by direct DNA sequencing. Patients were then risk stratified based on the genotypic prevalence in our database. Those homozygous for all 3 SNPs had only one possible haplotype resulting in a defined risk. Heterozygous patients had >1 possible haplotype and, thus, a range of risk was estimated. A "G" allele in rs3825942 (G153D) has the strongest association with XFS and, when combined with a "G" in rs1048661 (R141L) and "T" in rs2165241, the risk of XFS increases to 700 times that of the normal population. This was defined as high risk. Other levels of risk were defined as in the table.

 
Results:
 

There were 9 women and 8 men (mean age: 59.6±9 years). 5 high risk subjects had GG, GG, TT in R153D, R141L and rs2165241 respectively (GGT haplotype). One patient was classified as medium risk with GA, GG, and CT genotypes. 5 low risk patients had GG, GT, CC genotypes respectively. 2 patients defined as very low risk had genotype AA for G153D. The risk of the remaining 4 patients could not be determined due to their heterozygous genotypes for 2 or more SNPs, resulting in a wide range of possible haplotypes.

 
Conclusions:
 

This is the first time genetic analysis of LOXL1 polymorphisms has been used for risk stratification of XFSS patients. Although patients homozygous for GGT are at significantly increased risk, determining the prognosis of developing XFS is limited by the low specificity of the genetic markers. Further studies of XFS are warranted to identify markers that may improve the diagnostic yield of genetic screening.  

 
Keywords: gene screening • genetics • gene/expression 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×